Science & Technology
Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells
Department of Health and Human Services — National Institutes of Health
Opportunity #: 2R44DK133008-02
Award Ceiling
$915K
Award Floor
$915K
Close Date
Jul 31, 2027
503 days leftTotal Funding
$915K
Expected Awards
1
Posted Date
Sep 10, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-2R44DK133008-02
Description
SBIR Phase Phase II award: "Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells" awarded to Regenerative Medical Solutions Inc in Park Ridge, Illinois. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $915,136. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.